Innoviva Company Profile (NASDAQ:INVA)

About Innoviva (NASDAQ:INVA)

Innoviva logoInnoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:INVA
  • CUSIP: 88338T10
  • Web:
  • Market Cap: $1.32 billion
  • Outstanding Shares: 109,354,000
Average Prices:
  • 50 Day Moving Avg: $12.64
  • 200 Day Moving Avg: $11.68
  • 52 Week Range: $8.67 - $14.55
  • Trailing P/E Ratio: 19.13
  • Foreward P/E Ratio: 8.45
  • P/E Growth: 0.15
Sales & Book Value:
  • Annual Revenue: $149.88 million
  • Price / Sales: 8.82
  • Book Value: ($3.06) per share
  • Price / Book: -3.95
  • EBIDTA: $120.94 million
  • Net Margins: 44.57%
  • Return on Equity: -20.31%
  • Return on Assets: 19.38%
  • Debt-to-Equity Ratio: -2.03%
  • Current Ratio: 17.36%
  • Quick Ratio: 12.47%
  • Average Volume: 1.51 million shs.
  • Beta: 2.33
  • Short Ratio: 16.11

Frequently Asked Questions for Innoviva (NASDAQ:INVA)

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

How were Innoviva's earnings last quarter?

Innoviva Inc (NASDAQ:INVA) released its quarterly earnings results on Thursday, April, 27th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.27 by $0.12. The company earned $40.50 million during the quarter, compared to analysts' expectations of $47.66 million. Innoviva had a net margin of 44.57% and a negative return on equity of 20.31%. Innoviva's revenue was up 67.4% on a year-over-year basis. During the same period last year, the firm posted $0.09 earnings per share. View Innoviva's Earnings History.

Where is Innoviva's stock going? Where will Innoviva's stock price be in 2017?

2 equities research analysts have issued twelve-month price objectives for Innoviva's shares. Their predictions range from $11.00 to $16.00. On average, they expect Innoviva's share price to reach $13.50 in the next twelve months. View Analyst Ratings for Innoviva.

Are investors shorting Innoviva?

Innoviva saw a decrease in short interest in April. As of April 13th, there was short interest totalling 9,337,021 shares, a decrease of 51.5% from the March 31st total of 19,263,567 shares. Based on an average trading volume of 2,616,136 shares, the days-to-cover ratio is presently 3.6 days. Approximately 12.5% of the company's stock are short sold.

Who are some of Innoviva's key competitors?

Who owns Innoviva stock?

Innoviva's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.16%), BlackRock Inc. (11.16%), Vanguard Group Inc. (6.73%), Sarissa Capital Management LP (3.13%), First Eagle Investment Management LLC (2.86%) and State Street Corp (2.17%). Company insiders that own Innoviva stock include Eric Desparbes, James L Tyree, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.

Who sold Innoviva stock? Who is selling Innoviva stock?

Innoviva's stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, Goldman Sachs Group Inc., State of New Jersey Common Pension Fund D, American Century Companies Inc., JPMorgan Chase & Co., Credit Suisse AG, First Trust Advisors LP and SG Americas Securities LLC. Company insiders that have sold Innoviva stock in the last year include Eric Desparbes, Theodore J Jr Witek and Theodore L Witek Jr. View Insider Buying and Selling for Innoviva.

Who bought Innoviva stock? Who is buying Innoviva stock?

Innoviva's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Vanguard Group Inc., Sarissa Capital Management LP, FMR LLC, Rafferty Asset Management LLC, Morgan Stanley and State Street Corp. View Insider Buying and Selling for Innoviva.

How do I buy Innoviva stock?

Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Innoviva stock cost?

One share of Innoviva stock can currently be purchased for approximately $12.09.

Analyst Ratings

Consensus Ratings for Innoviva (NASDAQ:INVA) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $13.50 (11.66% upside)

Analysts' Ratings History for Innoviva (NASDAQ:INVA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/1/2017Cowen and CompanySet Price TargetBuy$16.00LowView Rating Details
3/14/2017Robert W. BairdReiterated RatingNeutral$11.00MediumView Rating Details
10/5/2015Morgan StanleyReiterated RatingOverweight$7.00 -> $9.00N/AView Rating Details
9/10/2015Sanford C. BernsteinReiterated RatingMarket Perform$15.00N/AView Rating Details
9/9/2015Bank of America CorpDowngradeBuy -> Neutral$16.00 -> $13.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Innoviva (NASDAQ:INVA)
Earnings by Quarter for Innoviva (NASDAQ:INVA)
Earnings History by Quarter for Innoviva (NASDAQ:INVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017$0.27$0.15$47.66 million$40.50 millionViewN/AView Earnings Details
2/9/2017Q4 2016$0.19$0.22$40.72 million$43.60 millionViewListenView Earnings Details
10/27/2016Q316$0.19$0.16$38.71 million$33.30 millionViewListenView Earnings Details
7/28/2016Q216$0.12$0.17$31.13 million$32.47 millionViewListenView Earnings Details
4/28/2016Q116$0.09$0.04$28.61 million$24.17 millionViewListenView Earnings Details
2/3/2016Q415$0.01$0.04$20.17 million$22.80 millionViewN/AView Earnings Details
10/28/2015Q315($0.03)($0.04)$15.23 million$13.56 millionViewListenView Earnings Details
7/29/2015Q2($0.06)($0.07)$10.90 million$10.70 millionViewListenView Earnings Details
5/6/2015Q115($0.08)($0.09)$8.64 million$6.90 millionViewListenView Earnings Details
2/18/2015Q414($0.14)($0.14)$5.42 million$7.30 millionViewN/AView Earnings Details
10/30/2014Q314($0.15)($0.19)$5.06 million$1.00 millionViewN/AView Earnings Details
8/18/2014($0.53)($0.18)ViewN/AView Earnings Details
8/6/2014Q214($0.53)($0.18)$4.39 million$0.93 millionViewN/AView Earnings Details
5/6/2014Q114($0.53)($0.62)$4.52 million$0.17 millionViewN/AView Earnings Details
2/6/2014Q413($0.38)($0.46)$6.03 million$1.60 millionViewN/AView Earnings Details
10/24/2013Q313$0.69($0.44)$3.08 million$0.44 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.46)($0.37)$1.43 million$1.33 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.38)($0.39)$2.71 million$1.34 millionViewN/AView Earnings Details
2/12/2013Q4 2012($0.36)($0.33)$3.88 million$5.80 millionViewN/AView Earnings Details
10/30/2012($0.39)($0.37)ViewN/AView Earnings Details
7/31/2012($0.42)($0.42)ViewN/AView Earnings Details
4/26/2012$1.02$0.93ViewN/AView Earnings Details
2/9/2012($0.38)($0.45)ViewN/AView Earnings Details
10/27/2011($0.33)($0.37)ViewN/AView Earnings Details
7/28/2011($0.27)($0.31)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Innoviva (NASDAQ:INVA)
Current Year EPS Consensus Estimate: $1.08 EPS
Next Year EPS Consensus Estimate: $1.43 EPS


Dividend History by Quarter for Innoviva (NASDAQ:INVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Innoviva (NASDAQ:INVA)
Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 77.62%
Insider Trades by Quarter for Innoviva (NASDAQ:INVA)
Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)
Insider Trades by Quarter for Innoviva (NASDAQ:INVA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Eric DesparbesCFOSell1,825$11.85$21,626.25View SEC Filing  
5/22/2017Theodore J Jr. WitekVPSell7,815$12.01$93,858.15View SEC Filing  
2/21/2017Eric DesparbesCFOSell1,825$12.07$22,027.75View SEC Filing  
11/22/2016Theodore L Witek JrVPSell3,700$10.84$40,108.00View SEC Filing  
11/21/2016Eric DesparbesCFOSell1,800$10.89$19,602.00View SEC Filing  
8/22/2016Eric DesparbesCFOSell3,700$11.77$43,549.00View SEC Filing  
5/18/2016James L TyreeDirectorSell813$10.47$8,512.11View SEC Filing  
5/11/2015Plc GlaxosmithklineMajor ShareholderBuy85,579$1,369,260.00$117,179,901,540.00View SEC Filing  
8/13/2014Junning LeeVPSell53,424$22.50$1,202,040.00View SEC Filing  
8/12/2014Bradford J ShaferSVPSell28,156$22.13$623,092.28View SEC Filing  
8/11/2014Bradford J ShaferSVPSell27,108$22.12$599,628.96View SEC Filing  
9/12/2013Rick WinninghamCEOSell22,353$40.03$894,790.59View SEC Filing  
7/30/2013Mathai MammenSVPSell7,000$36.51$255,570.00View SEC Filing  
6/7/2013Bradford J ShaferSVPSell31,038$35.04$1,087,571.52View SEC Filing  
5/29/2013David L BrinkleyInsiderSell3,808$35.01$133,318.08View SEC Filing  
5/13/2013David L BrinkleyInsiderSell16,129$40.33$650,482.57View SEC Filing  
8/7/2012Michael W AguiarCFOSell60,000$27.04$1,622,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Innoviva (NASDAQ:INVA)
Latest Headlines for Innoviva (NASDAQ:INVA)
DateHeadline logoInnoviva Inc (INVA) CFO Eric Desparbes Sells 1,825 Shares - May 23 at 8:35 PM logoInnoviva Inc (INVA) VP Theodore J. Jr. Witek Sells 7,815 Shares - May 23 at 8:18 PM logo Analysts Anticipate Innoviva Inc (INVA) Will Post Earnings of $0.28 Per Share - May 16 at 12:22 AM logoSeth Klarman Sells Innoviva Days After Activist Stakeholder Defeat - May 11 at 6:32 PM logoInnoviva Inc (INVA) Given a $16.00 Price Target at Cowen and Company - May 1 at 9:10 PM logoInnoviva Inc (INVA) Issues Quarterly Earnings Results, Misses Expectations By $0.12 EPS - April 29 at 1:25 AM logoEdited Transcript of INVA earnings conference call or presentation 27-Apr-17 9:00pm GMT - April 28 at 6:54 PM logoInvestor Network: Innoviva, Inc. to Host Earnings Call - April 27 at 6:32 PM logoInnoviva Reports First Quarter 2017 Financial Results - April 27 at 6:32 PM logoInnoviva misses 1Q profit forecasts - April 27 at 6:32 PM logo$49.33 Million in Sales Expected for Innoviva Inc (INVA) This Quarter - April 27 at 12:54 PM logoShort Interest in Innoviva Inc (INVA) Drops By 51.5% - April 27 at 7:16 AM logoSarissa Asks Innoviva Directors To Explain Continued Director Over-Compensation Despite Promises To Cut Costs - April 26 at 7:24 PM logoZacks: Brokerages Expect Innoviva Inc (INVA) Will Post Earnings of $0.26 Per Share - April 25 at 9:39 AM logoInnoviva, Inc. – Value Analysis (NASDAQ:INVA) : April 24, 2017 - April 24 at 5:35 PM logoSarissa Takes Innoviva to Court Over Busted Agreement - April 22 at 5:30 PM logoInnoviva (INVA) Receives Response to Board Challenge in Statement from Sarissa Capital Management - April 21 at 10:51 PM logoSarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents - April 21 at 10:38 AM logoOverwhelming Majority Of Non-GSK Shareholders Support Sarissa Capital And Not Innoviva Board And Management - April 21 at 10:38 AM logoInnoviva to Report First Quarter Financial Results on April 27 at 5:00 p.m. EDT - April 21 at 10:38 AM logoInnoviva, Inc. breached its 50 day moving average in a Bearish Manner : INVA-US : April 21, 2017 - April 21 at 10:38 AM logoHere's Why Innoviva Inc. Lost 10% Today - April 20 at 6:34 PM logoInnoviva (INVA) Declines to Add 2 Sarissa Nominees to Board - April 20 at 11:25 AM logoInnoviva prevails in proxy fight against activist Sarissa-source - April 20 at 11:25 AM logoInnoviva director vote drama hands last-minute loss to Sarissa - April 20 at 11:25 AM logoInnoviva Announces Preliminary Results of Annual Meeting - April 20 at 11:25 AM logoInnoviva Says It Fends Off Sarissa Dissidents - April 20 at 11:25 AM logoInnoviva Reneges On Accepted Deal With Sarissa Capital - April 19 at 10:49 PM logoInnoviva Urges Shareholders to Vote “FOR” All of Innoviva’s Value-Creating Directors On the WHITE Proxy Card TODAY - April 19 at 11:23 AM logoSarissa Capital States: Innoviva Already Appears To Renege On Cost Cuts; Innoviva Thinks Its Bad Corporate Governance Is Not A Problem - April 17 at 5:18 PM logoInnoviva Board Recommends Shareholders Vote “FOR” All of Innoviva’s Qualified Directors on the WHITE Proxy Card - April 17 at 10:49 AM logoSarissa Urges Shareholders To See Through Innoviva's Last Minute Flip-Flop On Cost Cuts; Notes Conspicuous Absence Of Promises To Fix Bad Corporate Governance - April 17 at 10:49 AM logoShort Interest in Innoviva Inc (INVA) Decreases By 6.9% - April 14 at 9:40 AM logoSarissa Capital Urges Shareholders Of Innoviva, Inc.: Follow The ... - April 14 at 9:25 AM logoSarissa Capital Urges Shareholders Of Innoviva, Inc.: Follow The Recommendations Of ISS, Glass Lewis And Egan-Jones; Vote On The Gold Card For Sarissa Nominees - April 13 at 5:41 PM logoInnoviva to Undertake Comprehensive Review of its Cost and Executive Compensation Structures - April 13 at 5:41 PM logoSarissa Capital Files Presentation In Proxy Contest With Innoviva - April 12 at 6:37 PM logoEgan-Jones Supports All Three Sarissa Capital Nominees For Innoviva Board - April 12 at 9:01 AM logoSarissa Capital Is Concerned That Innoviva Will Waste Shareholder Money On Imprudent Acquisitions - April 11 at 11:50 AM logoSarissa Capital Compelled To Clarify Egregious Misstatements Made By Innoviva - April 10 at 5:39 PM logoInnoviva Announces $50 Million Partial Royalty Notes Redemption - April 10 at 10:59 AM logoISS Supports All Three Sarissa Capital Nominees For Innoviva Board - April 10 at 10:59 AM logoInnoviva Comments on ISS and Glass Lewis Reports - April 10 at 10:59 AM logoAfter Hours Most Active for Apr 7, 2017 : INVA, FCX, XRX, FTR, CNP, INTC, OSG, ODP, HBI, RF, MU, NWSA - Nasdaq - April 7 at 5:49 PM logoSarissa Capital's Innoviva (INVA) Board Nominees Supported by Proxy Advisory Firm Glass Lewis - - April 7 at 5:49 PM logoGlass Lewis Supports Sarissa Capital's Nominees For Innoviva Board - April 7 at 10:28 AM logoNewman Ferrara LLP Announces Corporate Governance Investigation of Innoviva, Inc. - INVA - April 3 at 4:47 PM logoInnoviva's (INVA) Outperform Rating Reiterated at Cowen and Company - March 30 at 6:58 PM logoSarissa calls for Innoviva CEO, board pay cut - March 30 at 6:19 PM logoActivist investor Sarissa seeks Innoviva CEO pay cut - March 30 at 6:19 PM



Innoviva (INVA) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff